Incidental gallbladder cancer diagnosis confers survival advantage irrespective of tumour stage and characteristics.
Gallbladder cancer
Gallbladder cancer survival
Incidental gallbladder cancer
Non-incidental gallbladder cancer
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
14 May 2022
14 May 2022
Historique:
received:
13
11
2021
revised:
22
01
2022
accepted:
26
03
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
ppublish
Résumé
Incidental gallbladder cancer (IGBC) represents 50%-60% of gallbladder cancer cases. Data are conflicting on the role of IGBC diagnosis in oncological outcomes. Some studies suggest that IGBC diagnosis does not affect outcomes, while others that overall survival (OS) is longer in these cases compared to non-incidental diagnosis (NIGBC). Furthermore, some studies reported early tumour stages and histopathologic characteristics as possible confounders, while others not. To investigate the role of IGBC diagnosis on patients' overall survival, especially after surgical treatment with curative intent. Retrospective analysis of all patient referrals with gallbladder cancer between 2008 and 2020 in a tertiary hepatobiliary centre. Statistical comparison of patient and tumour characteristics between IGBC and NIGBC subgroups was performed. Survival analysis for the whole cohort, surgical and non-surgical subgroups was done with the Kaplan-Meier method and the use of log rank test. Risk analysis was performed with univariable and multivariable Cox regression analysis. The cohort included 261 patients with gallbladder cancer. 65% of cases had NIGBC and 35% had IGBC. A total of 90 patients received surgical treatment (66% of IGBC cases and 19% of NIGBC cases). NIGBC patients had more advanced T stage and required more extensive resections than IGBC ones. OS was longer in patients with IGBC in the whole cohort (29 IGBC diagnosis may confer a survival advantage independently of the pathological stage and tumour characteristics. Prospective studies are required to further investigate this, including detailed pathological analysis and molecular gene expression.
Sections du résumé
BACKGROUND
BACKGROUND
Incidental gallbladder cancer (IGBC) represents 50%-60% of gallbladder cancer cases. Data are conflicting on the role of IGBC diagnosis in oncological outcomes. Some studies suggest that IGBC diagnosis does not affect outcomes, while others that overall survival (OS) is longer in these cases compared to non-incidental diagnosis (NIGBC). Furthermore, some studies reported early tumour stages and histopathologic characteristics as possible confounders, while others not.
AIM
OBJECTIVE
To investigate the role of IGBC diagnosis on patients' overall survival, especially after surgical treatment with curative intent.
METHODS
METHODS
Retrospective analysis of all patient referrals with gallbladder cancer between 2008 and 2020 in a tertiary hepatobiliary centre. Statistical comparison of patient and tumour characteristics between IGBC and NIGBC subgroups was performed. Survival analysis for the whole cohort, surgical and non-surgical subgroups was done with the Kaplan-Meier method and the use of log rank test. Risk analysis was performed with univariable and multivariable Cox regression analysis.
RESULTS
RESULTS
The cohort included 261 patients with gallbladder cancer. 65% of cases had NIGBC and 35% had IGBC. A total of 90 patients received surgical treatment (66% of IGBC cases and 19% of NIGBC cases). NIGBC patients had more advanced T stage and required more extensive resections than IGBC ones. OS was longer in patients with IGBC in the whole cohort (29
CONCLUSION
CONCLUSIONS
IGBC diagnosis may confer a survival advantage independently of the pathological stage and tumour characteristics. Prospective studies are required to further investigate this, including detailed pathological analysis and molecular gene expression.
Identifiants
pubmed: 35664962
doi: 10.3748/wjg.v28.i18.1996
pmc: PMC9150056
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1996-2007Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
Références
J Surg Oncol. 2008 Dec 1;98(7):485-9
pubmed: 18802958
HPB (Oxford). 2019 Aug;21(8):1046-1056
pubmed: 30711243
Asian Pac J Cancer Prev. 2014;15(3):1281-3
pubmed: 24606453
World J Surg. 2004 Jul;28(7):692-6
pubmed: 15175901
PLoS One. 2016 Nov 15;11(11):e0166361
pubmed: 27846279
HPB (Oxford). 2014 Jul;16(7):641-7
pubmed: 24279377
Ann Surg Oncol. 2020 Apr;27(4):1132-1142
pubmed: 31741109
Ann Surg Oncol. 2021 Mar;28(3):1466-1480
pubmed: 32749621
J Gastrointest Surg. 2012 Jul;16(7):1311-7
pubmed: 22570074
Langenbecks Arch Surg. 2020 Aug;405(5):573-584
pubmed: 32458141
Ann Surg. 2007 Jun;245(6):893-901
pubmed: 17522515
Ann Surg Oncol. 2015 Aug;22(8):2779-86
pubmed: 25519930
Eur J Med Res. 2009 Aug 12;14(8):345-51
pubmed: 19666394
Surgery. 2017 Sep;162(3):515-524
pubmed: 28629653
Ann Surg. 2000 Oct;232(4):557-69
pubmed: 10998654
J Clin Med. 2020 May 14;9(5):
pubmed: 32423156
HPB (Oxford). 2015 Aug;17(8):681-90
pubmed: 26172135
Ann Surg. 2011 Aug;254(2):320-5
pubmed: 21617582
J Clin Oncol. 2019 Apr 20;37(12):1015-1027
pubmed: 30856044
World J Surg. 2009 Oct;33(10):2161-5
pubmed: 19636610
N Am J Med Sci. 2012 Jul;4(7):293-9
pubmed: 22866265
HPB (Oxford). 2020 Sep;22(9):1339-1348
pubmed: 31899044
Hepatogastroenterology. 2012 Jan-Feb;59(113):31-5
pubmed: 22251520
J Gastrointest Surg. 2007 Nov;11(11):1478-86; discussion 1486-7
pubmed: 17846848
Ann Surg Oncol. 2009 Apr;16(4):806-16
pubmed: 18985272
J Hepatobiliary Pancreat Surg. 2009;16(2):204-15
pubmed: 19219399
J Hepatol. 2018 May;68(5):959-969
pubmed: 29360550
J Gastrointest Oncol. 2015 Oct;6(5):452-8
pubmed: 26487937
Am Surg. 2017 Jul 1;83(7):679-686
pubmed: 28738935
J Korean Surg Soc. 2012 Oct;83(4):227-36
pubmed: 23091795
Int J Surg. 2014;12 Suppl 2:S108-S119
pubmed: 25182380
HPB (Oxford). 2008;10(6):446-58
pubmed: 19088932
Eur J Cancer Prev. 2019 Jan;28(1):1-9
pubmed: 28683010